Stomach (Gastric) Cancer: Causes, H. pylori, and Integrative Strategies for Digestive Health

Meta Description: Stomach cancer is closely linked to H. pylori infection, diet, and gut health. Learn about its causes, warning signs, treatment options, and evidence-based integrative strategies for digestive health and cancer prevention.

Introduction

Stomach cancer — also called gastric cancer — was once the most common cancer in the world. While its global incidence has declined dramatically over the past century (largely due to refrigeration, reduced salt-preserved food consumption, and H. pylori eradication), it remains the fifth most common cancer worldwide and the fourth leading cause of cancer death globally.

In the United States, stomach cancer is less common but carries a sobering prognosis: most cases are diagnosed at an advanced stage because early gastric cancer rarely causes symptoms. Understanding the biology, the critical role of Helicobacter pylori, dietary risk factors, and the evidence for integrative prevention is essential knowledge for anyone focused on digestive health and cancer prevention.

What Is Stomach Cancer?

The stomach is a muscular, J-shaped organ that receives food from the esophagus, mixes it with digestive acids and enzymes, and passes it to the small intestine. Stomach cancer arises from the cells lining the stomach wall.

The vast majority — approximately 90–95% — are adenocarcinomas, arising from the glandular cells of the stomach lining. These are further classified by location (cardia vs. non-cardia) and histologic type (intestinal vs. diffuse, per Lauren classification):

• Intestinal type — more common; associated with H. pylori, dietary factors, and chronic atrophic gastritis; tends to occur in older patients; better prognosis
• Diffuse type — less common but more aggressive; includes signet ring cell carcinoma; more common in younger patients and women; associated with CDH1 (E-cadherin) mutations in hereditary cases; worse prognosis

Less common types include gastrointestinal stromal tumors (GISTs), gastric lymphoma (MALT lymphoma — directly caused by H. pylori), and carcinoid tumors.

How Common Is It?

• Approximately 26,000 new cases diagnosed annually in the U.S.
• Lifetime risk: roughly 1 in 95
• 5-year survival: ~36% overall; ~77% for localized disease — but only ~25% of U.S. cases are caught at this stage
• Globally, highest rates in East Asia (Japan, South Korea, China), Eastern Europe, and South America
• Japan and South Korea have dramatically better outcomes due to national screening programs that detect early gastric cancer

The H. pylori Connection — A Bacterial Cause of Cancer

Helicobacter pylori is a gram-negative bacterium that colonizes the stomach lining of approximately 44% of the global population. It is classified by the WHO as a Group 1 carcinogen — a definitive cause of cancer — and is responsible for approximately 75–80% of non-cardia gastric cancers.

H. pylori causes cancer through a multi-step process (Correa cascade):

1. Chronic active gastritis
2. Chronic atrophic gastritis
3. Intestinal metaplasia
4. Dysplasia
5. Invasive adenocarcinoma

This process takes decades, which is why gastric cancer typically presents in older adults. Critically, eradicating H. pylori reduces gastric cancer risk by ~35–40% — one of the most powerful cancer prevention interventions available.

H. pylori is also the primary cause of gastric MALT lymphoma — a lymphoma that can be cured simply by eradicating the bacteria with antibiotics, without chemotherapy or radiation.

Risk Factors

Non-Modifiable

• H. pylori infection — the dominant risk factor (modifiable through testing and treatment)
• Age — most cases diagnosed after 65
• Sex — men are twice as likely to develop gastric cancer
• Race/ethnicity — higher rates in Asian Americans, Hispanic Americans, and African Americans
• Family history — first-degree relatives with gastric cancer increase risk 2–3x
• Hereditary diffuse gastric cancer (HDGC) — CDH1 gene mutations; lifetime risk up to 70–80%; prophylactic gastrectomy recommended
• Lynch syndrome — also increases gastric cancer risk
• Pernicious anemia — autoimmune destruction of gastric parietal cells; associated with increased risk
• Prior gastric surgery — partial gastrectomy increases risk of cancer in the gastric remnant

Modifiable

• Diet high in salt and salt-preserved foods — salted fish, pickled vegetables, cured meats; damages the gastric mucosa and promotes H. pylori virulence
• Diet high in processed and red meat — nitrosamines formed from nitrates/nitrites are gastric carcinogens
• Low fruit and vegetable intake — antioxidants and vitamin C are protective
• Smoking — doubles the risk; synergistic with H. pylori
• Heavy alcohol consumption
• Obesity — particularly for cardia (upper stomach) gastric cancer
• Occupational exposures — coal mining, rubber and metal processing

Warning Signs and Symptoms

Early gastric cancer is almost always asymptomatic. Advanced disease may present with:

• Persistent indigestion or heartburn (new onset in older adults warrants evaluation)
• Feeling full quickly after eating (early satiety)
• Nausea and vomiting
• Unexplained weight loss
• Abdominal pain or discomfort, particularly in the upper abdomen
• Difficulty swallowing (dysphagia) — for cardia tumors
• Blood in the stool or black, tarry stools (melena)
• Vomiting blood (hematemesis)
• Fatigue and anemia

"Alarm symptoms" — unintentional weight loss, dysphagia, persistent vomiting, hematemesis, or melena — require urgent endoscopic evaluation.

Diagnosis

• Upper endoscopy (EGD) — gold standard; allows direct visualization and biopsy of suspicious lesions
• H. pylori testing — urea breath test, stool antigen test, or biopsy-based testing; should be performed in all patients with gastric cancer or high-risk conditions
• CT scan — for staging; assesses lymph node involvement and distant metastasis
• Endoscopic ultrasound (EUS) — for T and N staging of localized disease
• Laparoscopy — to detect peritoneal metastasis not visible on CT
• HER2 testing — ~15–20% of gastric cancers overexpress HER2; targeted therapy available
• PD-L1 and MSI testing — for immunotherapy eligibility

Conventional Treatment

• Endoscopic resection — endoscopic mucosal resection (EMR) or endoscopic submucosal dissection (ESD) for early gastric cancer confined to the mucosa; curative with excellent outcomes
• Surgery — total or subtotal gastrectomy with D2 lymph node dissection; standard for resectable gastric cancer
• Perioperative chemotherapy — FLOT (docetaxel, oxaliplatin, leucovorin, 5-FU) before and after surgery; significantly improves survival
• Adjuvant chemoradiation — for patients who did not receive neoadjuvant therapy
• Targeted therapy — trastuzumab (Herceptin) for HER2-positive advanced gastric cancer; ramucirumab (anti-VEGFR2) for second-line
• Immunotherapy — nivolumab + chemotherapy is now preferred first-line for advanced gastric cancer; pembrolizumab for MSI-H/dMMR tumors; remarkable responses in MSI-H cases
• H. pylori eradication — standard of care for all H. pylori-positive patients; triple or quadruple antibiotic therapy

The Gut Microbiome and Gastric Cancer

Beyond H. pylori, the broader gastric and intestinal microbiome plays an increasingly recognized role in gastric cancer:

• H. pylori disrupts the gastric microbiome, promoting dysbiosis that accelerates the Correa cascade
• Nitrate-reducing bacteria in the stomach convert dietary nitrates to carcinogenic nitrosamines
• A diverse, balanced microbiome — supported by fiber, fermented foods, and probiotics — may be protective
• Gut microbiome composition influences immunotherapy response in gastric cancer

Evidence-Based Integrative Strategies

🥦 Dietary Approaches

• High fruit and vegetable intake — consistently associated with reduced gastric cancer risk; vitamin C inhibits nitrosamine formation and may suppress H. pylori
• Allium vegetables — garlic and onions have shown particularly strong inverse associations with gastric cancer risk in multiple meta-analyses; allicin has direct anti-H. pylori activity
• Cruciferous vegetables — sulforaphane has demonstrated anti-H. pylori activity and anti-gastric cancer effects in preclinical and early clinical studies
• Green tea — EGCG inhibits H. pylori adhesion and has anti-gastric cancer activity; high green tea consumption in Japan may partly explain lower gastric cancer mortality despite high H. pylori prevalence
• Limit salt and salt-preserved foods — one of the most evidence-based dietary changes for gastric cancer prevention
• Limit processed and red meat — reduces nitrosamine exposure
• Fermented foods — yogurt, kefir, kimchi, miso; support microbiome diversity; some evidence for reduced gastric cancer risk

🌿 Key Nutraceuticals

🏃 Lifestyle Factors

• Test and treat H. pylori — the single most impactful prevention strategy; consider testing if you have a family history of gastric cancer, chronic dyspepsia, or are from a high-prevalence region
• Quit smoking — synergistic with H. pylori in promoting gastric cancer
• Reduce salt intake — aim for <2,300mg sodium/day; avoid heavily salted and pickled foods
• Exercise — associated with reduced gastric cancer risk; supports healthy weight and immune function
• Maintain healthy weight — particularly important for cardia gastric cancer prevention
• Limit alcohol — damages gastric mucosa and promotes H. pylori virulence
• Manage GERD — chronic acid reflux is a risk factor for cardia gastric cancer and esophageal adenocarcinoma

Nutritional Support After Gastrectomy

Total or subtotal gastrectomy profoundly affects digestion and nutrition. Key considerations:

• Small, frequent meals — 6–8 small meals daily; the stomach's reservoir function is lost
• Dumping syndrome — rapid gastric emptying causes nausea, sweating, and diarrhea; managed with low-sugar, low-simple-carbohydrate diet and lying down after meals
• Vitamin B12 deficiency — intrinsic factor is lost after total gastrectomy; B12 injections or high-dose sublingual B12 are required for life
• Iron deficiency — reduced gastric acid impairs iron absorption; supplementation often needed
• Calcium and vitamin D — reduced absorption; supplementation essential
• Fat-soluble vitamins (A, D, E, K) — may be malabsorbed; monitor and supplement
• Protein optimization — essential for recovery and muscle preservation; aim for 1.2–1.5g/kg body weight

Repurposed Compounds & Emerging Investigational Approaches

A growing number of integrative and functional medicine practitioners are exploring repurposed compounds as adjunctive tools in gastric cancer support. Stomach cancer's well-defined biology — H. pylori-driven NF-κB/STAT3 activation, HER2 overexpression (~15–20%), VEGFR2-driven angiogenesis, MSI-H immunotherapy responsiveness, and the gut microbiome connection — provides excellent mechanistic targets for several repurposed agents. This section is strictly educational and does not constitute medical advice or a treatment recommendation. Individuals interested in these approaches should work with a qualified, integrative-minded physician.

🔬 Antiparasitic Agents

💊 Low Dose Naltrexone (LDN)

Low Dose Naltrexone (typically 1.5–4.5 mg taken at bedtime) transiently blocks opioid receptors, triggering a rebound upregulation of the body's endogenous opioid system — specifically the OGF (opioid growth factor) – OGFr (OGF receptor) axis, which directly regulates gastric epithelial and cancer cell proliferation.

• OGF-OGFr signaling has been shown to inhibit DNA synthesis in gastrointestinal cancer cell lines — Dr. Ian Zagon (Penn State) has published extensively on OGF's role in gastrointestinal cancer biology
• LDN modulates immune function via TLR4 pathway modulation — particularly relevant for gastric cancer, where H. pylori activates TLR4 signaling to drive NF-κB-mediated chronic inflammation and carcinogenesis; LDN's TLR4 modulation may reduce this inflammatory drive
• NK cell activation by LDN supports immune surveillance — important for detecting residual gastric cancer cells after surgery and for enhancing nivolumab and pembrolizumab immunotherapy responses
• LDN's anti-inflammatory effects may reduce the chronic gastric inflammation (from H. pylori, diet, smoking) that drives the Correa cascade
• Dr. Paul Marik's FLCCC cancer protocols include LDN as a standard adjunctive recommendation across gastrointestinal malignancies
• Research hub: LDNResearchTrust.org and LowDoseNaltrexone.org

LDN is generally well-tolerated, inexpensive, and available via compounding pharmacy with a prescription. It must not be taken with opioid medications. Post-gastrectomy patients should note that altered gastric emptying may affect naltrexone absorption — discuss timing with your prescribing physician.

🌿 CBD & Full Extract Cannabis Oil (FECO)

Cannabinoids interact with the endocannabinoid system (ECS) through CB1 and CB2 receptors, which are expressed on gastric cancer cells and gastric mucosal cells.

• CB1 and CB2 receptor activation has been shown to induce apoptosis in gastric cancer cell lines and inhibit tumor cell migration and invasion
• CBD has demonstrated anti-proliferative and pro-apoptotic effects in preclinical gastric cancer models; may reduce VEGF production and angiogenesis
• Cannabinoids may modulate NF-κB and STAT3 signaling — directly relevant to H. pylori-driven gastric carcinogenesis
• CB1 activation in the gastric mucosa has gastroprotective effects — reducing acid secretion and gastric mucosal inflammation; potentially relevant for managing gastritis and post-gastrectomy symptoms
• FECO (Full Extract Cannabis Oil) — containing the full spectrum of cannabinoids, terpenes, and flavonoids — may produce synergistic entourage effects beyond isolated CBD
• Dr. Dustin Sulak (Healer.com) is among the most prominent integrative physicians documenting cannabinoid use in oncology support, emphasizing individualized dosing and full-spectrum formulations
• Note: cannabinoid metabolism via CYP3A4 may interact with docetaxel, oxaliplatin, trastuzumab, and ramucirumab — discuss with your oncologist before use. Post-gastrectomy patients may have altered cannabinoid absorption.

🦠 Repurposed Antibiotics — Mitochondrial Targeting

Gastric cancer stem cells (the drug-resistant population responsible for recurrence after surgery and chemotherapy) are dependent on oxidative phosphorylation (OxPhos) for energy, making mitochondrial-targeting antibiotics mechanistically relevant.

• Doxycycline and azithromycin inhibit mitochondrial biogenesis in cancer stem cells, starving them of energy production
• Gastric cancer stem cells (CD44+, CD133+, LGR5+ populations) are particularly OxPhos-dependent and represent the population that survives FLOT chemotherapy and surgery — driving recurrence and peritoneal metastasis
• Groundbreaking research by Dr. Michael Lisanti and Dr. Federica Sotgia (University of Salford) demonstrated that doxycycline selectively targets cancer stem cells across multiple tumor types with minimal effect on normal cells
• Dr. Marco Fiorillo has published on the mitochondrial targeting hypothesis in gastrointestinal oncology contexts
• A 2017 paper in Oncotarget (Lamb et al.) demonstrated that doxycycline reduced cancer stem cell populations by up to 90% in certain models

Important note: doxycycline is also used in H. pylori eradication regimens (as part of quadruple therapy). Antibiotic use carries considerations around microbiome disruption — particularly important given the gut microbiome's role in gastric cancer and immunotherapy response. Probiotic support is essential. Post-gastrectomy patients may have altered doxycycline absorption.

Subtype-Specific Integrative Considerations

🧬 The Functional 13 Protocol: A Practitioner-Informed Integrative Stack

The Functional 13 Protocol is an integrative support framework built around 13 compounds — a combination of repurposed antiparasitic agents, nutraceuticals, and immune modulators — that have individually demonstrated preclinical or mechanistic relevance to cancer biology. Below is an educational overview of each compound and its proposed mechanistic relevance to stomach cancer specifically.

Conclusion

Stomach cancer is a disease where the intersection of infection, diet, and gut health is more clearly defined than almost any other cancer. Testing for and eradicating H. pylori, reducing salt and processed meat intake, eating a diverse plant-rich diet, and supporting the gut microbiome are not just theoretical recommendations — they are evidence-based actions with real preventive power. For those navigating active gastric cancer, repurposed compounds targeting STAT3, NF-κB, Wnt/β-catenin, VEGFR2, and gastric cancer stem cells offer meaningful mechanistic leverage — always in partnership with a qualified integrative oncologist. Your stomach is the gateway to your health. Protect it with intention.

This article is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before making changes to your health regimen. Some supplements may interact with gastric cancer treatments or be affected by post-gastrectomy absorption changes — always disclose all supplements to your oncology team.

References

• Siegel RL et al. (2023). Cancer Statistics. CA: A Cancer Journal for Clinicians.
• Plummer M et al. (2015). Global burden of gastric cancer attributable to Helicobacter pylori. International Journal of Cancer.
• Correa P. (1992). Human gastric carcinogenesis: a multistep and multifactorial process. Cancer Research.
• Jang HJ et al. (2004). Inhibitory activity of garlic components on Helicobacter pylori. Journal of Antimicrobial Chemotherapy.
• Dang Y et al. (2019). Sulforaphane and gastric cancer. Oncology Letters.
• Dogra N et al. (2019). Fenbendazole acts as a moderate microtubule destabilizing agent and causes cancer cell death by modulating multiple cellular pathways. Scientific Reports.
• Juarez M et al. (2020). Ivermectin as an antitumor agent: a systematic review. Pharmacological Research.
• Yo YT et al. (2012). Growth inhibition of ovarian tumor-initiating cells by niclosamide. Molecular Cancer Therapeutics.
• Doudican N et al. (2011). Mebendazole induces apoptosis via Bcl-2 inactivation in chemoresistant melanoma cells. Molecular Medicine.
• Padayatty SJ et al. (2004). Vitamin C pharmacokinetics: implications for oral and intravenous use. PNAS.
• Skrott Z et al. (2017). Alcohol-abuse drug disulfiram targets cancer via p97 segregase adaptor NPL4. Nature.
• Eliaz I et al. (2007). The effect of modified citrus pectin on urinary excretion of toxic elements. Integrative Cancer Therapies.
• Standish LJ et al. (2008). Trametes versicolor mushroom immune therapy in breast cancer. Journal of the Society for Integrative Oncology.
• Lamb R et al. (2017). Doxycycline down-regulates DNA-PK and radiosensitizes tumor initiating cells. Oncotarget.
• Arafa el-SA et al. (2011). Thymoquinone up-regulates PTEN expression and induces apoptosis in doxorubicin-resistant human breast cancer cells. International Journal of Molecular Sciences.
• Gu JW et al. (2009). EGCG, a major green tea catechin, suppresses breast tumor angiogenesis and growth via inhibiting the activation of HIF-1α and NFκB. Cancer Prevention Research.
• Nambiar DK et al. (2015). Silibinin preferentially radiosensitizes prostate cancer by inhibiting DNA damage response. Pharmaceutical Research.
• Tsuda H et al. (2002). Lactoferrin as a factor for prevention of cancer. Biochemistry & Cell Biology.